Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
May 23, 2022 08:30 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 16:30 ET
|
Day One Biopharmaceuticals, Inc.
Initial data from pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG) expected in June 2022 Company plans to initiate pivotal Phase 3 FIREFLY-2 clinical...
Day One to Present at the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 08:30 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Progress
March 07, 2022 07:30 ET
|
Day One Biopharmaceuticals, Inc.
Initial data from pivotal FIREFLY-1 study with DAY101 (tovorafenib) expected in June 2022 Targeted enrollment achieved in pivotal FIREFLY-1 study Topline results from pivotal FIREFLY-1 study...
Day One to Participate in the Cowen 42nd Annual Health Care Conference
February 28, 2022 16:05 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors
November 22, 2021 07:00 ET
|
Day One Biopharmaceuticals, Inc.
Phase 1b/2 Study Evaluating DAY101 in Combination with Pimasertib, Day One’s MEK Inhibitor, Expected to Begin in First Quarter of 2022 SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) --...
Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 18, 2021 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Reports Third Quarter 2021 Financial Results and Corporate Progress
November 08, 2021 16:50 ET
|
Day One Biopharmaceuticals, Inc.
Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022 Upcoming CTOS Meeting to Highlight Single Agent Activity of...
Day One Announces Presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting
November 03, 2021 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...